Roquefort Therapeutics (LON:ROQ) Shares Down 1% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ) shares were down 1% during trading on Friday . The stock traded as low as GBX 2.08 ($0.03) and last traded at GBX 2.08 ($0.03). Approximately 1,005,907 shares traded hands during trading, a decline of 53% from the average daily volume of 2,129,146 shares. The stock had previously closed at GBX 2.10 ($0.03).

Roquefort Therapeutics Trading Down 15.2%

The firm has a market capitalization of £2.80 million, a price-to-earnings ratio of -282.54 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07. The firm’s 50-day simple moving average is GBX 1.81 and its 200 day simple moving average is GBX 1.68.

Roquefort Therapeutics (LON:ROQ) last announced its quarterly earnings data on Tuesday, September 30th. The company reported GBX (0.33) EPS for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 29.57%.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.